Regentis Biomaterials Ltd (RGNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 06-2025 | 12-2024 | 12-2023 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,648 | -3,228 | 4,801 | -4,132 | -1,330 |
| Depreciation Amortization | 0 | N/A | 0 | 0 | -110 |
| Accounts payable and accrued liabilities | N/A | -33 | N/A | N/A | N/A |
| Other Working Capital | 131 | 129 | -1,599 | 709 | 5,720 |
| Other Operating Activity | 12,142 | 2,792 | -3,843 | 2,203 | -8,260 |
| Operating Cash Flow | $-1,375 | $-340 | $-641 | $-1,220 | $-3,980 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | N/A | 0 | 0 | 1,530 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -500 |
| Investing Cash Flow | $0 | $N/A | $0 | $0 | $1,030 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 300 | N/A | N/A | N/A |
| Other Financing Activity | 8,524 | 0 | 525 | 325 | 4,410 |
| Financing Cash Flow | $8,524 | $300 | $525 | $325 | $4,410 |
| Beginning Cash Position | 229 | 229 | 345 | 1,240 | 2,580 |
| End Cash Position | 7,378 | 189 | 229 | 345 | 4,040 |
| Net Cash Flow | $7,149 | $-40 | $-116 | $-895 | $1,460 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,375 | -340 | -641 | -1,220 | -3,980 |
| Free Cash Flow | -1,375 | -340 | -641 | -1,220 | -3,980 |